Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Xentria, Inc.

Home Clinical Trial Sponsors and OrganizationsXentria, Inc.

Xentria, Inc.

ACTIVE

2071 N Southport Ave Pmb 201, 伊利诺伊州库克县, 伊利诺伊州, United Stateswww.xentria.comHolding11–50 employees

Also known as:

Xentria

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

9

50.0%

Phase 2

5

27.8%

Phase 3

2

11.1%

Phase 4

2

11.1%

Trial Status Distribution

Active, not recruiting

2

11.1%

Completed

5

27.8%

Not yet recruiting

2

11.1%

Recruiting

6

33.3%

Withdrawn

3

16.7%

Clinical Trials

Trials sponsored by this organization (18)

An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Not yet recruiting

Oct 2026182 participants

A Study to Investigate the Pharmacokinetics and Safety of KM04 Compared to United States (US)-Gonal-f Revised Formulation Female (RFF) Redi-ject and European Union (EU)-Gonal-f in Healthy Adult Female Volunteers

Not yet recruiting

Oct 202642 participants

A study to investigate the pharmacokinetics and safety of KM04 compared to US-Gonal-f RFF Redi-ject and EU-Gonal-f in healthy adult female volunteers

Feb 202648 participants

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®

Oct 202554 participants

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

Oct 2025440 participants

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®

Oct 2024114 participants

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®

Jul 202454 participants

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

Jun 2024225 participants

Page 1 of 3

Approvals

No approval data available

News

Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan), a Biosimilar to NovoLog

- The FDA has approved Garzulys™ (insulin aspart-fsan), a rapid-acting human insulin analog biosimilar to NovoLog®, for glycemic control in adults and pediatric patients with diabetes mellitus. - Meitheal Pharmaceuticals served as the U.S. Regulatory Agent and holds exclusive U.S. commercialization rights under a license agreement with Emerge Bioscience, the BLA holder. - The approval represents a milestone in Meitheal's strategic expansion from generic injectables into complex biologics and branded products. - Garzulys was developed through a multi-company collaboration involving Tonghua Dongbao, NKF, Xentria, and Meitheal, with two additional insulin biosimilar candidates in the pipeline.

On this page

Overview
Clinical Trials18
Approvals
News1

Back to Organizations